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Introduction
Type 2 diabetes mellitus and its major complication, renal 
disease, represent one of the most signiﬁcant contemporary 
health problems facing Australia’s Indigenous Aboriginal 
People.1-3 The overall prevalence of type 2 diabetes is at 
least three to four times that of the general population.1 
Hospitalisation rates for diabetes are four times higher for 
Aboriginal males and six times higher for Aboriginal females 
compared to non-Aboriginal people. Across Australia, diabetes 
is responsible for 10.6 times more deaths in Indigenous 
males and 17.6 times more deaths in Indigenous females 
than the broader Australian community.2 Rates of end-stage 
renal failure (principally as a result of diabetic nephropathy) 
have risen almost unabated across the past 15 years in many 
Aboriginal communities.4-9
As part of an Australian Government-funded national 
program called QAAMS which began in 1999, Aboriginal 
Health Workers from 65 Aboriginal medical services across 
Australia conduct on-site POCT for HbA
1c
 on the DCA 2000 
analyser (Bayer Diagnostics, Tarrytown, NY, USA) to monitor 
glycaemic control in Aboriginal people with established 
diabetes.10-12 Aboriginal health workers are Aboriginal people 
living and working in the community who have a basic 
qualiﬁcation in primary health care. 75% of the participating 
Aboriginal medical services are located in rural and remote 
Australia. 
In 2003, the QAAMS program expanded to include POC 
urine ACR testing on the DCA 2000 to further support 
diabetes management.13 Urine ACR is a biochemical marker 
for microalbuminuria or early stages of renal disease which, 
as mentioned previously, is the major complication of diabetes 
in Aboriginal people. The initial intake of Aboriginal medical 
services into the QAAMS urine ACR program was capped by 
the Australian Government at 30, all of whom were existing 
sites within the QAAMS HbA
1c
 program. From January 
2006, this capping has now been increased to a maximum of 




The ability to perform both HbA
1c
 and urine ACR tests on-
site by POCT provides a powerful and culturally effective 
platform to improve diabetes management in Australia’s 
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Abstract
Type 2 diabetes mellitus and its major complication, renal disease, represent one of the most signiﬁcant contemporary health 
problems facing Australia’s Indigenous Aboriginal People. The Australian Government-funded Quality Assurance for Aboriginal 
Medical Services Program (QAAMS) provides a framework by which on-site point-of-care testing (POCT) for haemoglobin 
A1c (HbA
1c
) and now urine albumin:creatinine ratio (ACR) can be performed to facilitate better diabetes management in 
Aboriginal medical services. This paper provides updated evidence for the analytical quality of POCT in the QAAMS Program. 
The median imprecision for point-of-care (POC) HbA
1c
 and urine ACR quality assurance (QA) testing has continually improved 
over the past six and half years, stabilising at approximately 3% for both analytes and proving analytically sound in Aboriginal 
hands. For HbA
1c
, there was no statistical difference between the imprecision achieved by QAAMS and laboratory users of the 
Bayer DCA 2000 since the QAAMS program commenced (QAAMS CV 3.6% ± 0.52, laboratory CV 3.4% ± 0.42; p = 0.21, 
paired t-test). The Western Paciﬁc Island of Tonga recently joined the QAAMS HbA
1c
 Program indicating that the QAAMS 
model can also be applied internationally in other settings where the prevalence of diabetes is high.
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Aboriginal people.14 However, it is also crucial that analytical 
performance for conducting POCT in the Aboriginal (non-
laboratory) setting meets acceptable analytical performance 
standards. To measure and maintain the analytical quality of 
POCT in the QAAMS Program, a broad quality management 
framework was established. This included a culturally 
appropriate education and training program with practical 
and written competency assessment for POCT operators, an 
internal quality control program and external quality assurance 
(EQA) testing for HbA
1c
 and urine ACR. This paper provides 
updated evidence on the analytical quality of POCT in the 
QAAMS Program, speciﬁcally assessed by the results of EQA 
testing, and also mentions the international applicability of 
the model.
Methods
The QAAMS Program is a collaborative partnership between 
the Community Point-of-Care Services Unit within the 
Flinders University Rural Clinical School and the Royal 
College of Pathologists of Australasia (RCPA) Quality 
Assurance Programs Pty Ltd, Chemical Pathology Group, 
Adelaide, Australia. The QA component of the QAAMS 
HbA
1c
 and urine ACR programs is modelled on the same 
principles used by the RCPA Quality Assurance Programs in 
delivering QA programs for laboratories. However selected 
design elements have been modiﬁed to suit the Aboriginal 
POCT environment, which, for example, does not have access 
to deionised water or volumetric pipettes for reconstituting 
quality assurance samples. Each QAAMS participant is 
thus provided with lyophilised QA samples and either eye 
droppers (for HbA
1c
) or sealed plastic tubes (for urine ACR) 
with a speciﬁc volume of deionised water for making up the 
samples. Two samples per month are tested across two six-
monthly testing cycles per year. The samples for each cycle 
comprise paired and linearly-related levels of analyte across a 
range of concentrations from 5 to 14% for HbA
1c
 and 1 to 25 
mg/mmol for urine ACR. The use of paired samples enables 
calculation of imprecision for QA testing on the DCA 2000 
for both individual services and the group as a whole.
Services receive a monthly summary report shortly after the end 
of each month. The report format, which has been published 
previously, summarises both short and long term analytical 
performance.10,13 Each site has its own Community Number 
to ensure conﬁdentiality of results. At the end of each month, 
the QA results from all participating services are reviewed. If 
the QA results returned by a particular service are outside the 
limits of acceptability established by the program organisers 
(± 0.5 up to an HbA
1c
 of 10% and ± 5% at HbA
1c
 >10%, and ± 
15% for urine ACR), the service’s previous results are assessed 
for trends over recent months, the service is contacted and the 
possible reasons for the poor performance are discussed with 
the POCT operator. Poorly performed services are monitored 
closely until their performance improves. The QAAMS 
Program also has a telephone support service (attended during 
normal business hours). Using this service, POCT operators 
can contact a member of the QAAMS management team to 
discuss any technical or analytical issue as it arises.
At the completion of each six-monthly cycle, key performance 
indicators are calculated including:
• Participation Rate (number of QA results returned as 
a % of the maximum number of results that could be 
returned).
• % Acceptable Results (the % of results within preset 
limits of acceptability set by the QAAMS management 
team, as stated previously). 
• Median within-site imprecision (CV%), calculated 
by dividing the standard deviation of the midpoint 
of the service’s range of concentrations, expressed 
as a percentage. Imprecision is considered a crucial 
performance indicator because serial POCT HbA
1c
 and 
urine ACR measurements are conducted for patient 
management in the QAAMS program. It is important 
that analytical noise is minimised and does not mask 
clinically signiﬁcant changes in patient results across 
time. Current guidelines for Aboriginal and Torres Strait 
Islander Peoples recommend that HbA
1c
 is conducted 
every three months, while urine ACR is performed 
annually if the patient has a normal ACR and six monthly 
if the patient has microalbuminuria.15
• Median within-site bias, which is the average of biases 
of the service’s line of best ﬁt at the lowest, highest 
and midpoint concentrations, irrespective of sign. For 
HbA
1c
 samples, a target value was assigned to each 
sample using an international primary reference method 
for HbA
1c
 (DCCT Biorex 70 HPLC).16 For urine ACR 
samples, the median of all results submitted for each 
sample was used as the target because no international 





 QA testing, the participation rate across 13 six-
monthly testing cycles from July 1999 to December 2005 
has averaged 86% (range 73 to 89%). Eighty ﬁve percent of 
6148 QA results submitted over these 13 testing cycles were 
within the preset limits of acceptability. The median within-
site imprecision (CV%) achieved by services has consistently 
improved over the six and a half years since the program 
began (Figure 1), averaging 3.6% across the lifetime of the 
program and 3.2% across the past three years. Within-site 
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accuracy has remained steady, with the median bias averaging 
0.22% (range 0.17 to 0.38%) across the 13 testing cycles. 
 
It is possible to directly compare the performance of QAAMS 
Aboriginal medical services with laboratory users of the 
DCA 2000 (of which there are approximately 70) because the 
QAAMS and the laboratory-based RCPA Glycohaemoglobin 
QAP use the same material. The performance achieved for QA 
testing by Aboriginal medical services and laboratories using 
the DCA 2000 across the past six and a half years are shown 
in the Table. The median CV% for laboratory users of the 
DCA 2000 has averaged 3.4% since 1999 and 3.2% across the 
past three years. There was no statistical difference between 
the median CV% achieved by QAAMS and laboratory users 
of the DCA 2000 since the QAAMS program commenced 
(QAAMS 3.6% ± 0.52, laboratory 3.4% ± 0.42; t = 1.96, df = 
12, p = 0.21, paired t-test).
For urine ACR QA testing, the participation rate across six 
6-monthly testing cycles from January 2003 to December 
2005 has averaged 85% (range 74 to 91%). Ninety six percent 
of 1754 QA results submitted over these six testing cycles 
were within the preset limits of acceptability. The median 
imprecision (CV%) achieved by services for urine ACR 
testing has consistently improved over the three years since 
the program began (Figure 2), averaging 4.4% across the 
lifetime of the program and 2.9% over the past two years. 
Within-site accuracy has remained steady, with the median 
bias averaging 0.42% (range 0.28 to 0.62%) across the six 
testing cycles.
Discussion
The results presented in this paper conﬁrm that the QAAMS 
model for POCT HbA
1c
 and urine ACR testing provides 
a health service delivery system that is analytically sound 
in Aboriginal hands. The imprecision achieved for HbA
1c
 
QA testing by Aboriginal health workers has continually 
improved across the duration of the QAAMS Program and was 
statistically equivalent to that achieved by trained laboratory 
scientists and technicians using the DCA 2000 point-of-care 
analyser. 
Precision goals for HbA
1c
 methods have continually been 
reﬁned downwards over the past decade as the clinical 
requirement for tight imprecision has been highlighted 
through the results of international studies such as the 
Diabetes Control and Complications Trial (DCCT) and the 
UK Prospective Diabetes Study.17,18 The minimum precision 
goal for POC HbA
1c
 testing recommended by the Australian 
Government Department of Health and Ageing’s Interim 
Standards for Point-of-Care Testing in General Practice is 4% 
and represents a consensus of published information.19 Many 
professional bodies have recommended a desired precision 
goal of 3% for laboratory HbA
1c
 methods, as this degree of 
precision can statistically distinguish between recommended 
HbA
1c
 treatment goals of 7% and 8%.20-22 A recent international 
workshop advocated the optimal precision goal for laboratory 
HbA
1c
 methods should be 2% because this level of precision 
‘justiﬁes clinicians acting on differences of 0.35% to 0.5% as 
being signiﬁcant’.23,24 As can be seen in Figure 1, QAAMS 
participants achieved a precision base which was just outside 
the minimum goal in the ﬁrst year of the program. Over the 
next three and a half years, services achieved a precision base 
Figure 1. Median Precision Achieved by Aboriginal Medical Services in the QAAMS Program for POC HbA1c testing from 
1999-2005.
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that was well within the minimum goal. In 2004, they achieved 
better than the desired goal of 3%. Over the past year, median 
performance for HbA
1c
 QA testing in the QAAMS program 
has stabilised at around the 3% mark, potentially reaching 
the maximum analytical capability of the DCA 2000 POCT 
analyser. 
The minimum precision goal for POC urine ACR testing 
recommended by the Australian Government’s Department 
of Health and Ageing’s Interim Standards for Point-of-
Care Testing in General Practice is 12%, with this goal also 
representing a consensus of published information.19,21 As 
seen from Figure 2, this goal has also been readily achieved 
by Aboriginal medical services in the QAAMS program. 
The analytical performance recorded by QAAMS participants 
for these two tests represents an outstanding achievement, 
acknowledging that POCT in the QAAMS program is 
being undertaken by non-laboratory trained health workers 
from services scattered across Australia with many services 
enduring difﬁcult working conditions, particularly in remote 
Australia, and high rates of staff turnover. It reﬂects an on-
going commitment not only by the QAAMS management 
team to continuing education, training and competency 
assessment but also by the dedicated teams of Aboriginal 
health workers conducting POCT in their services. Whilst 
this paper has focused speciﬁcally on observed improvements 
in analytical quality, it should be noted that the QAAMS 
program has also been shown to be both culturally appropriate 
and clinically effective in improving glycaemic control in 
Aboriginal hands.14 In the long term, the QAAMS program 
aims to collect data on the impact of the program on reduction 
of morbidity and mortality.
The successful adaptation of the QAAMS model for 
urine ACR testing in 2003 demonstrates that the model is 
transferable to other POC tests. The Diabetes Centre from the 
Western Paciﬁc island of Tonga recently joined the QAAMS 
Table. Comparative precision base (median CV%) over the last equivalent 13 testing cycles: Aboriginal Medical Services (AMS) 
versus laboratories using the Bayer DCA 2000.










Program Year 1999 2000 2001 2002 2003 2004 2005
Cycle 1 2 3 4 5 6 7 8 9 10 11 12 13
 
                                Type of Service
            
QAAMS AMS 4.3 4.4 4.0 3.7 4.1 3.9 3.4 3.8 3.2 2.8 2.9 3.2 3.2
Glycohaemoglobin Labs 4.1 3.0 3.0 3.4 4.1 3.7 3.5 3.6 3.3 3.1 3.2 2.7 3.1
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network, with the approval of the Australian Government. The 
QAAMS Program Manager trained a team of health workers 
from Tonga at the Australian Centre for Diabetes Strategies. 
A high prevalence of diabetes (15%) has been reported in 
Tonga, where the disease causes similar problems to those 
faced by Aboriginal Australians.25 The Bayer DCA 2000 
offered a practical option for the Diabetes Centre to provide 
better care and monitoring for many of its diabetes patients. 
The results of recent QA testing in Tonga indicates that sound 
analytical performance for POCT HbA
1c
 testing can also be 
obtained in Indigenous health services outside Australia that 
have access to the same education, training and QA testing 
framework provided by QAAMS. This ﬁnding also conﬁrms 
the transferability of the QAAMS model to other health 
settings and illustrates the potential of this POCT model to be 
expanded internationally to support diabetes management in 
other countries where the burden of diabetes is similarly high 
or where health services have limited access to laboratory 
services due to geographic isolation. 
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In the 2005 May;26(ii)issue of the Journal, page 16 (Appendix) of the article “The Evidence Based Medicine 
Approach to Diagnostic Testing: practicalities and limitations” the reference for Search Findings: should be 
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